Abstract
Summary. Introduction. Children with oral and maxillofacial pathologies are at risk of local thrombotic events, which exacerbate the outcomes of surgical treatment. Aim: to assess the hemostasis in children with surgical oral and maxillofacial pathology using both conventional and integral methods. Materials and Methods. A retrospective observational study was conducted on 271 children with surgical oral and maxillofacial pathology. Prior to surgical intervention, demographic, clinical and laboratory data were collected as well as hemostasis studies were performed. The patients were divided into four groups: vascular malformations (n=115), inflammatory (n=66), hemangiomas (n=16), and controls (n=47). Results. The incidence of local thrombotic events in patients with vascular and inflammatory diseases was higher (padj = 0.001 and padj < 0.001, respectively) compared with the control group and amounted to 20% and 31.8%, respectively. The median hospital stay for children with thrombotic events was 24 [16; 33] days, while the median stay for those without thrombotic events was 12 [8; 19] days (p < 0.0001). In cases of vascular malformations and inflammatory conditions, thrombodynamics revealed spontaneous blood clots in the samples. The growth rate and the size of the blood clots exceeded the reference values. Conclusion. It is imperative to conduct comprehensive monitoring of hemostasis parameters. Conventional blood clotting tests are inadequate for detection of early signs of hypercoagulability. Integral methods for monitoring hemostasis are effective for the early diagnosis of thrombotic events. The thrombodynamic test better reveals the hypercoagulation potential hidden from other methods at the preoperative stage. Regional thrombotic events in surgical oral and maxillofacial pathology have been demonstrated to result in a doubling of the length of hospital stay.
For citation: Pavlova D.E., Leonov N.P., Madonov P.G., Trakhtman P.E., Iamatina S.V., Spiridonova E.A., Grachev N.S., Bulanov A.Y. Hemostasis in children with surgical oral and maxillofacial pathology. Tromboz, gemostaz i reologiya. 2024;(3):39–50. (In Russ.).
References
- Ricci K.W., Brandão LR. Coagulation issues in vascular anomalies. Semin Pediatr Surg. 2020;29(5):150966. DOI: 10.1016/j.sempedsurg.2020.150966.
- Wolberg A.S., Aleman M.M., Leiderman K., Machlus K.R. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited. Anesth Analg. 2012;114(2):275–85. DOI: 10.1213/ ANE.0b013e31823a088c.
- Kushner A., West W.P., Khan Suheb M.Z., Pillarisetty L.S. Virchow Triad. 2022 Dec 10. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2024. Available at: https://www.ncbi.nlm.nih.gov/ books/NBK539697/. [Accessed: 15.01.2024].
- Kluft C., Burggraaf J. Introduction to haemostasis from a pharmacodynamic perspective. Br J Clin Pharmacol. 2011;72(4):538– 46. DOI: 10.1111/j.1365-2125.2011.03946.x.
- Pokhabov D.S., Shestakov E.A., Fedyk O.V et al. Thromboelastography and coagulogram in a multidisciplinary hospital. Tromboz, gemostaz i reologiya. 2023;(3):38–44. (In Russ.). DOI: 10.25555/ THR.2023.3.1067.
- Mack J.M., Pierce C.D., Richter G.T et al. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography. Pediatr Blood Cancer. 2021;68(2):e28824. DOI: 10.1002/pbc.28824.
- Kapp F.G., Schneider C., Holm A. et al. Comprehensive analyses of coagulation parameters in patients with vascular anomalies. Biomolecules. 2022;12(12):1840. DOI: 10.3390/biom12121840.
- Franchi T., Eaton S., De Coppi P., Giuliani S. The emerging role of immunothrombosis in paediatric conditions. Pediatr Res. 2019;86(1):19–27. DOI: 10.1038/s41390-019-0343-6.
- Zhuo K.Y., Russell S., Wargon O., Adams S. Localised intravascular coagulation complicating venous malformations in children: Associations and therapeutic options. J Paediatr Child Health. 2017;53(8):737–41. DOI: 10.1111/jpc.13461.
- Ricci K.W., Chute C., Hammill A.M. et al. Retrospective study of hematologic complications in patients with slow-flow vascular malformations undergoing sclerotherapy. Pediatr Blood Cancer. 2020;67(10):e28277. DOI: 10.1002/pbc.28277.
